Live tape.Join the lounge

Research with context.

A clearer way to explore the market.

Create an account Contact the team

Market signals, research, watchlists, and alerts in one workspace.

Follow the signal.

Product Pricing FAQ

Data coverage Methodology Disclosures Contact

© 2026 Longbrunch. All rights reserved.

longbrunch/

1801.HK/Research

Fundamentals

Innovent Biologics Inc · Equity

Partial coverage

TradeShort termMedium termLong term

Financial health Growth Valuation Profitability Shareholder return

Financial health

2 current metrics

Total Assets2025-12-31: CN¥37.35B
Total Liabilities2025-12-31: CN¥17.99B

Historical trendData pending

Growth

4 current metrics

Eps2026-07-31: 0.55
Free Cash Flow2026-07-31: CN¥3.23B
Net Income2025-12-31: CN¥813.57M
Revenue2025-12-31: CN¥13.04B

Historical trendData pending

Valuation

3 current metrics

Market Cap2026-07-31: CN¥150.94B
Trailing Pe2026-07-31: 157.63635
Trailing P/E: 157.64

Historical trendData pending

Profitability

3 current metrics

Ebitda2026-07-31: CN¥1.31B
Gross Profit2025-12-31: CN¥11.29B
Operating Income2025-12-31: CN¥2.14B

Historical trendData pending

Shareholder return

3 current metrics

Payout Ratio2026-07-31: 0%
Trailing Annual Dividend Rate2026-07-31: 0.0
Trailing Annual Dividend Yield2026-07-31: 0%

Historical trendData pending

Financial evidence

Statement-level periods and line items live in the dedicated view.

Open Financial Statements →